nasdaq:snss
|
166198
|
Apr 21st, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 21st, 2024 03:17AM
|
Apr 21st, 2024 03:17AM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 20th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 20th, 2024 12:05AM
|
Apr 20th, 2024 05:39PM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 19th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 19th, 2024 04:40AM
|
Apr 19th, 2024 04:40AM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 18th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 18th, 2024 12:49AM
|
Apr 18th, 2024 07:00PM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 17th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 17th, 2024 12:03AM
|
Apr 17th, 2024 03:26PM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 16th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 15th, 2024 11:59PM
|
Apr 16th, 2024 11:42AM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 15th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 14th, 2024 11:54PM
|
Apr 15th, 2024 05:23PM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 14th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 13th, 2024 11:43PM
|
Apr 13th, 2024 11:43PM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 13th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 12th, 2024 11:35PM
|
Apr 13th, 2024 12:08PM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:snss
|
166198
|
Apr 12th, 2024 12:00AM
|
Sunesis Pharmaceuticals, Inc.
|
2.4K
|
43.00
|
Open
|
|
Apr 11th, 2024 11:41PM
|
Apr 12th, 2024 09:04AM
|
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
Open
|
|
Open
|
395 Oyster Point Blvd.
|
South San Francisco
|
CA
|
US
|
94080
|
|
Sunesis Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|